ArticleJournal of neuro-oncology2026
CD73 and PD-L1 expression in WHO grade 1 and grade 2 meningiomas: an exploratory analysis of purinergic and immune-related profiles.
Article in Journal of neuro-oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundMeningiomas are the most common primary central nervous system tumors and exhibit heterogeneous biological behavior across WHO grades. Emerging evidence suggests that purinergic signaling and immune-related pathways may contribute to meningioma biology.
objectiveThis study evaluated the expression and activity of CD39/ENTPD1 and CD73/NT5E, the expression of PD-L1/CD274, and the systemic inflammatory profile in patients undergoing surgical resection of meningiomas.
resultsForty patients were included, with specific subgroups available for molecular, immunohistochemical, enzymatic, and cytokine analyses. Molecular comparisons were restricted to WHO grade 1 and grade 2 tumors. NT5E/CD73 expression was higher in WHO grade 2 tumors at both mRNA and protein levels, whereas CD274/PD-L1 expression was lower. Peripheral CD39/CD73 enzymatic activity also differed between study groups, while plasma cytokines showed non-significant trends toward higher concentrations in patients with WHO grade 2 tumors.
conclusionGiven the cross-sectional design, small sample sizes for specific analyses, and the absence of direct measurements of adenosine signaling or longitudinal clinical outcomes, these findings should be interpreted as exploratory patterns associated with tumor grade rather than evidence of tumor progression or a causal mechanism of immune evasion. Overall, the results identify CD73 as a candidate biomarker associated with WHO grade, warranting validation in larger, longitudinal, and mechanistic studies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.